Chapter: 1 INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENT
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
1.4.4. Assumptions for growth scenarios
1.4.5. Expected pricing per dose for Zika virus vaccine
Chapter: 2 EXECUTIVE SUMMARY
2.1. CXO PERSPECTIVE
Chapter: 3 MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. TOP INVESTMENT POCKETS
3.3. ZIKA VIRUS-KEY FACTS
3.3.1. Mode of infection and transmission of Zika virus
3.3.1.1. From infected mother to child
3.3.1.2. Through sex
3.3.1.3. Through blood transfusion
3.3.1.4. Through laboratory and healthcare setting exposure
3.3.2. Signs and symptoms of infection
3.3.3. Prevention and control of Zika virus
3.3.3.1. Vector control options
3.3.3.1.1. Targeted residual spraying
3.3.3.1.2. Space spraying
3.3.3.2. Personal protection measures
3.3.4. Prevalence and incidence
3.3.5. Diagnosis and treatment of Zika virus
3.3.5.1. Trioplex real-time RT-PCR assay
3.3.5.2. Zika MAC-ELISA
3.4. REGULATION OF VACCINES BY FDA
3.4.1. Licensure of vaccines in U.S.
3.4.2. Priority Review Voucher System
3.4.3. U.S. licensed flavivirus vaccines
3.5. CLINICAL TRIALS
3.6. PRICING FOR TOP GLOBAL VACCINE PRODUCTS
3.7. MARKET OPPORTUNITIES
3.7.1. Surging need for medical solutions for the prevention & treatment of Zika-linked birth defects
3.7.2. High rate of incidence of active Zika virus infection
Chapter: 4 FORECAST SCENARIO ANALYSIS OF ZIKA VIRUS VACCINES
4.1. OVERVIEW
4.1.1. Market size and forecast
4.1.1.1. Rapid growth scenario
4.1.1.2. Moderate growth scenario
4.1.1.3. Low growth scenario
Chapter: 5 POTENTIAL ANALYSIS OF ZIKA VIRUS VACCINE MARKET, BY GEOGRAPHY
5.1. INTRODUCTION
5.2. NORTH AMERICA
5.2.1. Market size and forecast
5.3. EUROPE
5.3.1. Market size and forecast
5.4. ASIA-PACIFIC
5.4.1. Market size and forecast
5.5. LAMEA
5.5.1. Market size and forecast
Chapter: 6 POTENTIAL ANALYSIS OF ZIKA VIRUS VACCINES-BY COUNTRY
6.1. BRAZIL
6.1.1. Market size and forecast
6.2. MEXICO
6.2.1. Market size and forecast
6.3. PHILIPPINES
6.3.1. Market size and forecast
6.4. VIETNAM
6.4.1. Market size and forecast
6.5. THAILAND
6.5.1. Market size and forecast
6.6. REST OF THE WORLD
6.6.1. Market size and forecast
Chapter: 7 COMPANY PROFILES
7.1. BHARAT BIOTECH INTERNATIONAL LTD
7.1.1. Company overview
7.1.2. Company Snapshot
7.1.3. Operating business segments
7.1.4. Product pipeline
7.1.5. Research funding
7.1.6. Key strategic developments
7.2. GENEONE LIFE SCIENCE, INC.
7.2.1. Company overview
7.2.2. Company Snapshot
7.2.3. Operating business segments
7.2.4. Product pipeline
7.2.5. Key strategic developments
7.3. GLAXOSMITHKLINE PLC
7.3.1. Company overview
7.3.2. Company Snapshot
7.3.3. Operating business segments
7.3.4. Business performance
7.3.5. Key strategic developments
7.4. HAWAII BIOTECH INC
7.4.1. Company overview
7.4.2. Key strategic developments
7.4.3. Company Snapshot
7.4.4. Operating business segments
7.5. IMMUNOVACCINE INC.
7.5.1. Company overview
7.5.2. Company Snapshot
7.5.3. Operating business segments
7.5.4. Business performance
7.5.5. Product pipeline
7.5.6. Key strategic developments
7.6. INOVIO PHARMACEUTICALS, INC
7.6.1. Company overview
7.6.2. Company Snapshot
7.6.3. Operating business segments
7.6.4. Business performance
7.6.5. Product pipeline
7.6.6. Research funding
7.6.7. Key strategic developments
7.7. NEWLINK GENETICS CORPORATION
7.7.1. Company overview
7.7.2. Company Snapshot
7.7.3. Business performance
7.7.4. Product pipeline
7.8. SANOFI S.A.
7.8.1. Company overview
7.8.2. Company Snapshot
7.8.3. Operating business segments
7.8.4. Business performance
7.8.5. Product pipeline
7.8.6. Research funding
7.8.7. Key strategic developments
7.9. TAKEDA PHARMACEUTICAL CO., LTD.
7.9.1. Company overview
7.9.2. Company Snapshot
7.9.3. Operating business segments
7.9.4. Business performance
7.9.5. Product pipeline
7.9.6. Research funding